Zymeworks (NASDAQ:ZYME), a clinical-stage biotechnology company developing novel, bispecific antibody therapeutics, provided a strategic update outlining key priorities for 2026, anchored by recent clinical and regulatory progress for its lead candidate Ziihera (zanidatamab-hrii).
Natera (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, released preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2025.
USANA Health Sciences (NYSE:USNA), a global leader in nutritional supplements and wellness products sold through direct selling, today announced preliminary fiscal year 2025 net sales results and its initial net sales outlook for fiscal 2026 ahead of its presentation at the 28th Annual ICR Conference.
Amazon Pharmacy (NASDAQ:AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, now offers Novo Nordisk’s Wegovy® pill, the first and only FDA-approved oral GLP-1 for weight management, through many insurance plans as well as a transparent cash-pay option.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it has entered into an exclusive global license agreement with Pfizer (NYSE:PFE) for ervogastat (formerly PF-06865571), an oral diacylglycerol acyltransferase 2 (DGAT-2) inhibitor currently in Phase 2 development, as well as rights to two additional early-stage metabolic dysfunction-associated steatohepatitis (MASH) assets.
Boston-based Rhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, announced preliminary, unaudited net product revenues for its flagship therapy IMCIVREE (setmelanotide) for the fourth quarter and full year ended December 31, 2025.
Delcath Systems (NASDAQ:DCTH), an interventional oncology company specializing in treatments for primary and metastatic liver cancers, announced preliminary unaudited financial results and business updates for the fourth quarter and full year ended December 31, 2025.
Cartesian Therapeutics (NASDAQ:RNAC) provided an update on its Descartes-08 program, a first-in-class autologous mRNA-engineered CAR-T cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases, and outlined key 2026 priorities.
Schrödinger (NASDAQ:SGDR) announced a strategic collaboration with Eli Lilly and Company (NYSE:LLY) on Friday to integrate Lilly’s high-powered TuneLab™ AI platform directly into Schrödinger’s flagship enterprise software, LiveDesign.
Palvella Therapeutics (NASDAQ:PVLA) issued a comprehensive 2026 corporate update detailing significant progress across its late-stage QTORIN platform, which leverages a proprietary topical rapamycin formulation for the treatment of rare dermatological and vascular conditions.
Aquestive Therapeutics (NASDAQ:AQST) reported that the U.S. Food and Drug Administration has identified deficiencies in the new drug application for Anaphylm (dibutepinephrine), an oral sublingual film formulation for the emergency treatment of Type I allergic reactions, including anaphylaxis.
Perspective Therapeutics (NYSE:CATX) reported updated interim safety and efficacy data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET, a targeted alpha-particle radiopharmaceutical for the treatment of neuroendocrine tumors, with a data cut-off of December 10, 2025.
